SCHEMBL5761

SCHEMBL5761

CCC(C(=O)O)S(C)(=O)=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PMP22 Q01453 1/20 0.35
CHRM1 P11229 1/20 0.35
AKR1A1 P14550 1/20 0.35
CHRM3 P20309 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2C P28335 1/20 0.35
ADRA1A P35348 1/20 0.35
HRH1 P35367 1/20 0.35
DRD3 P35462 1/20 0.35
SLC6A3 Q01959 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
CA2 P00918 1/20 0.34
MAPK1 P28482 1/20 0.34
GCLC P48506 1/20 0.34
SLC1A3 P43003 1/20 0.33
SLC1A2 P43004 1/20 0.33
SLC1A1 P43005 1/20 0.33
MMP2 P08253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29029474 1.00 PMP22 (0.35) PMP22CHRM1AKR1A1CHRM3HTR2A
SCHEMBL16782030 0.80 PMP22 (0.42) PMP22CHRM1AKR1A1CHRM3HTR2A
SCHEMBL28224631 0.80 HDAC1 (0.48) PMP22CHRM1AKR1A1CHRM3HTR2A
SCHEMBL890709 0.79 CHRM1 (0.40) PMP22CHRM1AKR1A1CHRM3HTR2A
SCHEMBL7241006 0.79 CHRM1 (0.35) PMP22CHRM1AKR1A1CHRM3HTR2A
SCHEMBL16588883 0.78 PMP22 (0.37) PMP22GCLCSLC1A3SLC1A2SLC1A1
SCHEMBL5022363 0.77 CHRM1 (0.39) PMP22CHRM1AKR1A1CHRM3HTR2A
SCHEMBL5014288 0.77 CHRM1 (0.39) PMP22CHRM1AKR1A1CHRM3HTR2A
SCHEMBL5013300 0.77 CHRM1 (0.39) PMP22CHRM1AKR1A1CHRM3HTR2A
SCHEMBL1634572 0.77 MMP2 (0.35) PMP22CHRM1AKR1A1CHRM3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2014-03-20 US claimed
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 US claimed
WO-2023192356-A1 INTERMEDIATES USEFUL FOR THE PREPARATION OF AN LPXC ANALOG, AND PROCESSES FOR THEIR PREPARATION ZOETIS SERVICES LLC (US) 2023-10-05 WO disclosed
CN-116217426-A Method for synthesizing S-fluorobutyramide from (R) -2-sulfonyl butyrate alkyl ester 山东省农药科学研究院 2023-06-06 CN disclosed
CN-114591208-B Synthetic method of gamma-mercapto-beta-sulfonyl methyl butyrate 成都理工大学 2023-02-10 CN disclosed
CN-114591208-A Synthetic method of gamma-mercapto-beta-sulfonyl methyl butyrate 成都理工大学 2022-06-07 CN disclosed
US-20210053926-A1 SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-02-25 US disclosed
EP-3765027-A1 PYRIDINONE AND PYRIMIDINONE PHOSPHATES AND BORONATES USEFUL AS ANTIBACTERIAL AGENTS Pfizer Inc (US) 2021-01-20 EP disclosed
US-10781184-B2 Substituted benzazinones as antibacterial compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-09-22 US disclosed
WO-2019178305-A1 PYRIDINONE AND PYRIMIDINONE PHOSPHATES AND BORONATES USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2019-09-19 WO disclosed
CN-106573924-B Isoxazoline hydroxamic acid derivs as LpxC inhibitor 诺华股份有限公司 2019-06-25 CN disclosed
EP-1567489-A1 PYRROLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA GLAXO GROUP LIMITED (GB) 2005-08-31 EP disclosed
WO-2004052851-A1 PYRROLYDIN-2-ONE DERIVATIVES AS INHIBITORS OF THROMBIN AND FACTOR XA GLAXO GROUP LIMITED (GB) 2004-06-24 WO disclosed
EP-1389110-A2 INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME Avanir Pharmaceuticals (US) 2004-02-18 EP disclosed
US-20030195194-A1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same AVANIR PHARMACEUTICALS 2003-10-16 US disclosed
WO-2002094203-A2 INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND METHODS FOR IDENTIFYING THE SAME AVANIR PHARMACEUTICALS (US) 2002-11-28 WO disclosed
EP-0873123-A4 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIV PITTSBURGH (US) 1999-02-03 EP disclosed
EP-0873123-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1998-10-28 EP disclosed
WO-1997017070-A1 INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES UNIVERSITY OF PITTSBURGH (US) 1997-05-15 WO disclosed
EP-0576287-A1 Cosmetic compositions UNILEVER PLC (GB) 1993-12-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195194-A1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same MIF, MSR1, MMP12 PMP22 3858/4885CHRM1 2131/4885AKR1A1 1011/4885
US-20210053926-A1 SUBSTITUTED BENZAZINONES AS ANTIBACTERIAL COMPOUNDS LPXN, MLX, ZYX PMP22 695/4885CHRM1 4834/4885AKR1A1 2705/4885
US-10781184-B2 Substituted benzazinones as antibacterial compounds LPXN, MLX, ZYX PMP22 695/4885CHRM1 4834/4885AKR1A1 2705/4885
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS GRK5, GPBAR1, GPR55 PMP22 4772/4885CHRM1 114/4885AKR1A1 669/4885
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 PMP22 409/4885CHRM1 2403/4885AKR1A1 2166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.